ArticleAnnals of translational medicine2017
Predictors of response and resistance to checkpoint inhibitors in solid tumors.
Article in Annals of translational medicine, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Mechanisms of Resistance to Anti-PD-1 Immunotherapy in Melanoma and Strategies to Overcome It.Biomolecules · 2025Review
- Proteome and phosphoproteome signatures of recurrence for HPVCommunications medicine · 2022Article
- Deep Learning-Based Body Composition Analysis Predicts Outcome in Melanoma Patients Treated with Immune Checkpoint Inhibitors.Diagnostics (Basel, Switzerland) · 2021Article
- Intersection of FcγRIIB, the microbiome, and checkpoint inhibitors in antitumor immunity.Cancer immunology, immunotherapy : CII · 2021Review
- Cryoablation and Immunotherapy for Breast Cancer: Overview and Rationale for Combined Therapy.Radiology. Imaging cancer · 2021Review
- Checking autoimmune genetic risk to stratify immune checkpoint inhibitor responders.Proceedings of the National Academy of Sciences of the United States of America · 2020Article
- Optimizing oncolytic virotherapy in cancer treatment.Nature reviews. Drug discovery · 2019Review
- Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.Cancer drug resistance (Alhambra, Calif.) · 2019Review
Corrections and comments
- Comment on
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.